A Molecular Role for Lysyl Oxidase in Breast Cancer Invasion1
Total Page:16
File Type:pdf, Size:1020Kb
[CANCER RESEARCH 62, 4478–4483, August 1, 2002] A Molecular Role for Lysyl Oxidase in Breast Cancer Invasion1 Dawn A. Kirschmann,2 Elisabeth A. Seftor, Sheri F. T. Fong, Daniel R. C. Nieva, Colleen M. Sullivan, Elijah M. Edwards, Pascal Sommer, Katalin Csiszar, and Mary J. C. Hendrix Department of Anatomy and Cell Biology, Holden Comprehensive Cancer Center at The University of Iowa, The Roy J. and Lucille A. Carver College of Medicine, Iowa City, Iowa 52242-1109 [D. A. K., E. A. S., D. R. C. N., C. M. S., E. M. E., M. J. C. H.]; Institut de Biologie et Chimie des Prote´ines, Lyon Cedex 07, France [P. S.]; and Pacific Biomedical Research Center, University of Hawaii, Honolulu, Hawaii 96822 [S. F. T. F., K. C.] ABSTRACT LOX is a copper-dependent amine oxidase that initiates the cova- lent cross-linking of collagens and elastin in extracellular matrices We identified previously an up-regulation in lysyl oxidase (LOX) ex- (reviewed in Refs. 3, 4). It is secreted as a M 50,000 glycosylated pression, an extracellular matrix remodeling enzyme, in a highly invasive/ r proenzyme, which is proteolytically processed by procollagen C pro- metastatic human breast cancer cell line, MDA-MB-231, compared with MCF-7, a poorly invasive/nonmetastatic breast cancer cell line. In this teinase (bone morphogenic protein-1) into a mature, biologically study, we demonstrate that the mRNA expression of LOX and other LOX active Mr 32,000 form (3, 4). The formation of collagen/elastin family members [lysyl oxidase-like (LOXL), LOXL2, LOXL3, and cross-links by LOX leads to an increase in tensile strength and LOXL4] was observed only in breast cancer cells with a highly invasive/ structural integrity, and is essential for normal connective tissue metastatic phenotype but not in poorly invasive/nonmetastatic breast function, embryonic development, and wound healing (3, 5). Conse- cancer cells. LOX and LOXL2 showed the strongest association with quently, aberrant LOX expression or enzymatic activity leads to invasive potential in both highly invasive/metastatic breast cancer cell disease. Decreases in LOX expression or activity have been associated lines tested (MDA-MB-231 and Hs578T). To determine whether LOX with such heritable connective tissues disorders as Ehler-Danlos syn- is directly involved in breast cancer invasion, LOX antisense oligo- drome, cutis laxa, and Menkes’ syndrome (6–10). Increases in LOX nucleotides were transfected into MDA-MB-231 and Hs578T cells, and expression contribute to the development of fibrotic diseases such as found to inhibit invasion through a collagen IV/laminin/gelatin matrix in vitro compared with LOX sense oligonucleotide-treated and untreated arteriosclerosis, scleroderma, and liver cirrhosis, diseases that involve controls. In addition, treatment of MDA-MB-231 and Hs578T cells with connective tissue remodeling (11–14). -aminopropionitrile (an irreversible inhibitor of LOX enzymatic Although the ECM maturation activity of LOX has long been activity) decreased invasive activity. Conversely, MCF-7 cells transfected with thought to be its sole function, more recent evidence implicates the the murine LOX gene demonstrated a 2-fold increase in invasiveness that was involvement of LOX in many important biological functions other reversible by the addition of -aminopropionitrile in a dose-dependent than collagen/elastin cross-linking. LOX has been shown to induce manner. In addition, endogenous LOX mRNA expression was induced motility and migration in monocytes, vascular smooth muscle cells, when MCF-7 cells were cultured in the presence of fibroblast conditioned and fibroblasts (15–17). In addition, LOX may play a role in cell medium or conditioned matrix, suggesting a role for stromal fibroblasts in growth/differentiation as its expression is up-regulated by a number of LOX regulation in breast cancer cells. Moreover, the correlation of LOX growth factors and steroids (3, 4, 18). Moreover, a role for LOX in up-regulation and invasive/metastatic potential was additionally demon- strated in rat prostatic tumor cell lines, and human cutaneous and uveal transcriptional gene regulation and cellular transformation has also melanoma cell lines. These results provide substantial new evidence that been implicated as evidenced by localization of LOX protein and LOX is involved in cancer cell invasion. enzymatic activity to cell nuclei (19), potential utilization of histone H1 as a substrate (20), activation of the collagen III ␣1 promoter (21), and a putative tumor suppressor in nontumorigenic revertants of INTRODUCTION ras-transformed fibroblasts (reviewed in Ref. 3). In this study, we test the hypothesis that LOX expression contrib- In 2002, breast cancer is predicted to account for 31% of all of the utes to cellular invasive ability. The data demonstrate that LOX and diagnosed cancers in women, more than twice that of the second most other LOXL family members are specifically expressed by invasive/ common cancer (lung cancer; Ref. 1). Because metastasis is a major metastatic cancer cells compared with poorly invasive/nonmetastatic challenge in cancer management, it is critical to determine molecular cancer cells, and that modulation of LOX expression and function in markers that definitively distinguish tumors of nonmetastatic potential breast cancer cells affects in vitro cellular invasive activity. from those with metastatic potential. To identify such markers, a clearer understanding of the metastatic progression in breast cancer is MATERIALS AND METHODS required. To this end, we identified an up-regulation in LOX3 expres- sion in invasive/metastatic breast cancer cell lines compared with Cells and Culture Conditions. MCF-7 cells were kindly supplied by Dr. poorly invasive/nonmetastatic breast cancer cell lines (2). F. Miller (Karmanos Cancer Institute, Detroit, MI), and MDA-MB-231, T47D, and Hs578T cell lines were obtained from the American Type Culture Col- Received 2/15/02; accepted 5/23/02. lection (Manassas, VA). The cutaneous melanoma A375P and C8161 cell lines The costs of publication of this article were defrayed in part by the payment of page were kind gifts from Drs. I. J. Fidler (M.D. Anderson Cancer Center, Univer- charges. This article must therefore be hereby marked advertisement in accordance with sity of Texas, Houston, TX) and F. L. Meyskens, Jr. (University of California, 18 U.S.C. Section 1734 solely to indicate this fact. Irvine Cancer Center, Orange, CA), respectively. The uveal melanoma cell line 1 Supported by DAMD17-99-1-9225 (to D. A. K.), University of Iowa College of Medicine Grant (to D. A. K.), NIH/National Cancer Institute CA59702, Order of Eastern OCM-1 was kindly provided by Dr. J. Kan-Mitchell (Karmanos Cancer Insti- Star Breast Cancer Research Fund (to M. J. C. H.), NIH CA776580, and AR47713 tute), and M619 and C918 uveal melanoma cell lines were a kind gift from (to K. C.) Dr. K. Daniels (University of Iowa, Iowa City, IA). Human Rb foreskin 2 To whom requests for reprints should be addressed, at Department of Anatomy and fibroblasts were a generous gift from Dr. Gregory Goldberg (Washington Cell Biology, 1-100 BSB, University of Iowa, 51 Newton Road, Iowa City, IA 52242- Ј Ј Ј 1109. Phone: (319) 335-7655; Fax: (319) 335-7770; E-mail: dawn-kirschmann@ University, St. Louis, MO). Rat prostate cancer cell lines (5 P, 5 A, and 5 B) uiowa.edu. were derived and established from the R-3327 Dunning tumor in our labora- 3 The abbreviations used are: LOX, lysyl oxidase; Rb, foreskin fibroblast cell line; tory. Cell lines were maintained as described previously (22) and were har-   LOXL, lysyl oxidase-like; ECM, extracellular matrix; APN, -aminopropionitrile; RT- vested when cultures were ϳ80% confluent. PCR, reverse transcriptase-PCR; MICS, membrane invasion culture system; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; hLOX, human LOX; mLOX, murine LOX; RNA Isolation. Total RNA was isolated from breast cancer cell lines using aa, amino acid; cm, conditioned medium; cmtx, conditioned matrix. TRIzol RNA isolation reagent (Invitrogen), according to manufacturer’s spec- 4478 Downloaded from cancerres.aacrjournals.org on September 26, 2021. © 2002 American Association for Cancer Research. LYSYL OXIDASE IN BREAST CANCER INVASION ifications. Polyadenylated RNA was isolated from total RNA by binding to centrifuged (2000 rpm, 10 min), filtered (0.22 m) to remove residual cells and oligodeoxythymidine cellulose (Becton Dickinson, Bedford, MA), as de- cellular debris, and stored at Ϫ20°C until use. Conditioned matrices were scribed previously (23). generated by coating six-well tissue culture plates with 122 g of rat tail Semiquantitative RT-PCR Analysis. Reverse transcription of total RNA collagen I (BD Bioscience) and polymerizing with 100% ethanol for 5 min at from breast, prostate, and melanoma cancer cell lines was performed using the room temperature. Matrices were rehydrated with 1 ml of PBS for 5 min at Advantage PCR kit according to manufacturer’s instructions (BD Clontech, room temperature, and 5 ϫ 105 Rb fibroblasts were added to each well in Palo Alto, CA). PCR amplification was performed with LOX- and LOXL2- complete medium and cultured for 3 days at 37°C, 5% CO2. Wells were treated Ј specific primers: hLOX [accession S78694 forward: 5 -GATCCTGCTGATC- with 20 mM NH4OH for 10 min at room temperature to remove the cells and CGCGACAA-3Ј (bases 500–520); reverse: 5Ј-GGGAGACCGTACTG- subsequently washed three times with sterile water and two times with PBS. GAAGTAGCCAGT-3Ј (bases 843–868)], rat LOX [accession U11038 MCF-7 cells (5 ϫ 105 cells/well) were then added to conditioned matrices for forward: 5Ј-CAACCCGGAAATTACATTCTAAAGGTCAGTG-3Ј (bases an additional 3 days. Total RNA was harvested by adding 1 ml of TRIzol 1376–1405); reverse: 5Ј-CCTTCCTCAGCACCAAGTGTATCC-3Ј (bases reagent to each well. 1986–2009)], and hLOXL2 [accession NM_002318 forward: 5Ј-GGCCGC- Ј Ј CACGCGTG GATC-3 (bases 2093–2110); reverse: 5 -CCCAAGGGTCAG- RESULTS GTAGCAGCCCC-3Ј (bases 2752–2774)]. Annealing temperature and number of amplification cycles were optimized at 64°C and 30 cycles for LOX, and LOX Expression in Breast Cancer Cell Lines.